Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a study protocol synopsis for the Expanded Access Program (EAP) for its lead candidate drug, the HDAC inhibitor CS1, in the rare disease Pulmonary Arterial Hypertension (PAH), has been published. The EAP will support long-term documentation of safety and efficacy data of CS1 treatment in the Phase II study in PAH.The study protocol synopsis for the CS1-004 Expanded Access Study, titled; “Expanded Access, Open-Label, Safety Extension